Resource Summary Report

Generated by NIF on Sep 22, 2026

JIMT-1

RRID:CVCL_2077
Type: Cell Line

Proper Citation

RRID:CVCL_2077

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2077

Proper Citation: RRID:CVCL_2077

Description: Cell line JIMT-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: PMID:15634652, PMID:17334996, PMID:20215515, PMID:22460905, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26055192, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Characteristics: ER-negative. Has amplified ERBB2 and is insensitive to trastuzumab (Herceptin) (PubMed=15634652)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JIMT-1

Synonyms: JIMT1, JIMT

Cross References: BTO:BTO_0004312, CLO:CLO_0009912, EFO:EFO_0005388, AddexBio:C0006005/50, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:627, BioSample:SAMN03473040, BioSample:SAMN10989571, cancercelllines:CVCL_2077,

Cell_Model_Passport:SIDM01037, ChEMBL-Cells:CHEMBL4295430, ChEMBL-Targets:CHEMBL4296443, CLS:305433, Cosmic:1348959, Cosmic:2165010, Cosmic-CLP:1298157, DepMap:ACH-000711, DSMZ:ACC-589, DSMZCellDive:ACC-589, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1298157, GEO:GSM155212, GEO:GSM274696, GEO:GSM274707, GEO:GSM783975, GEO:GSM827173, GEO:GSM847393, GEO:GSM847489, GEO:GSM887183, GEO:GSM888256, GEO:GSM1172878, GEO:GSM1172971, GEO:GSM1374578, IARC_TP53:28224, LiGeA:CCLE_176, LINCS_HMS:51118, LINCS_LDP:LCL-1482, PharmacoDB:JIMT1_702_2019, PRIDE:PXD000691, PRIDE:PXD030304, Progenetix:CVCL_2077, PubChem_Cell_line:CVCL_2077, SLKBase:3562, Ubigene:YC-C046, Wikidata:Q54898927

ID: CVCL_2077

Record Creation Time: 20220427T220650+0000

Record Last Update: 20260920T004236+0000

Ratings and Alerts

No rating or validation information has been found for JIMT-1.

No alerts have been found for JIMT-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 194 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

El Sahili A, et al. (2026) Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity. Molecular cancer therapeutics.

Yang DM, et al. (2026) Isolation, Structural Elucidation, and Biological Evaluation of Homoisoflavonoids From Pterolobium Macropterum. Chemistry & biodiversity, 23(4), e71207.

Pougoue Ketchemen J, et al. (2026) Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer. British journal of cancer, 134(12), 1820.

Yamaguchi A, et al. (2026) Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. Antibody therapeutics, 9(2), 127.

Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. Molecular cancer therapeutics, 24(9), 1295.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell stem cell, 32(7), 1087.

Lin H, et al. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. Cell reports. Medicine, 6(5), 102117.

Yassin AA, et al. (2025) Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium. International journal of molecular sciences, 26(7).

Bednova O, et al. (2025) Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering. Biomolecules, 15(5).

Rask G, et al. (2025) Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ. BJC reports, 3(1), 73.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell.

Zähringer A, et al. (2025) AIstain: Enhancing microglial phagocytosis analysis through deep learning. Cell reports methods, 5(11), 101207.

Yamaguchi A, et al. (2025) 177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors. Molecular cancer therapeutics, 24(6), 907.

Palhares LCGF, et al. (2025) An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities. Journal of experimental & clinical cancer research : CR, 44(1), 49.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. Cancer research communications, 4(12), 3084.

Vinik Y, et al. (2024) Computational pipeline predicting cell death suppressors as targets for cancer therapy. iScience, 27(9), 110859.

Pougoue Ketchemen J, et al. (2024) Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. European journal of nuclear medicine and molecular imaging.

Petersen ME, et al. (2024) Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates. Molecular cancer therapeutics, 23(5), 606.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Molecular cell, 84(2), 261.

Peng H, et al. (2024) Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector

Cells on Assay Performance. Cancers, 16(13).